Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 12:9:614.
doi: 10.3389/fonc.2019.00614. eCollection 2019.

The Expression, Regulation, and Biomarker Potential of Glypican-1 in Cancer

Affiliations
Free PMC article
Review

The Expression, Regulation, and Biomarker Potential of Glypican-1 in Cancer

Sen Wang et al. Front Oncol. .
Free PMC article

Abstract

Glypican-1 (GPC-1) and other glypicans are a family of heparan sulfate proteoglycans. These proteins are highly expressed on the cell membrane and in the extracellular matrix, functioning mainly as modulators of growth factor signaling. Some of them are abnormally expressed in cancer, possibly involved in tumorigenesis, and detectable in blood as potential clinical biomarkers. GPC-1 is another glypican member that has been found to be associated with some cancers, and has increasingly interested the cancer field. Here we provide a brief review about GPC-1 in its expression, signaling and potential as a cancer biomarker.

Keywords: GPC-1; biomarker; cancer; glypican; heparan sulfate proteoglycan.

PubMed Disclaimer

Figures

Figure 1
Figure 1
GPC-1 modulates signaling pathways in cancer progression. The HS side chains of GPC-1 bind both growth factors (such as VEGF-A, FGF-2, and TGF-β) and their receptors, to facilitate their assembly for enhanced signaling in PI3K/AKT, MAPK, Smad pathways. GPC-1 can be cleaved by Notum and then released into the extracellular space, which can compete with the GPC-1 anchored on the cell membrane to inhibit its function.

Similar articles

Cited by

References

    1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. (2019) 144:1941–1953. 10.1002/ijc.31937 - DOI - PubMed
    1. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La K, et al. . Oncogenic signaling pathways in the cancer genome atlas. Cell. (2018) 173:321–37. 10.1158/1538-7445.AM2018-3302 - DOI - PMC - PubMed
    1. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. . Comprehensive characterization of cancer driver genes and mutations. Cell. (2018) 173:371–85. 10.1016/j.cell.2018.02.060 - DOI - PMC - PubMed
    1. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. Embo Rep. (2014) 15:1243–53. 10.15252/embr.201439246 - DOI - PMC - PubMed
    1. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. (2014) 14:430–9. 10.1038/nrc3726 - DOI - PMC - PubMed

LinkOut - more resources